Company profile
Innovation Pharmaceuticals Inc.
OTC: IPIX · Healthcare · Biotechnology
#1163 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 22GM —SS 36
v0.1 · 25/100 weight · pillars only
↑ listing tenure, return on assets · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
-$6.0k
Rev growth YoY (TTM)
-133.3%
Net income (FY)
-$3.2M
Employees
4
as of 2026-10-15
Market cap
$103.7k
as of 2026-10-15
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$3.2M-$3.2M2023
Operating income-$3.1M-$3.1M2023
Total assets$7.5M$7.5M2023
Liabilities$5.5M$5.5M2023
Equity$2.0M$2.0M2023
Revenue trend
FY2020 – FY2023 · USD
FY20
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Innovation Pharmaceuticals Inc.’s revenue?
Innovation Pharmaceuticals Inc. booked $0 in FY2023 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Genix Pharmaceuticals Corporation——Apptly Health Technologies Corp.——Agentix Corp.17DPond Technologies Holdings Inc.21DPlanet Based Foods Global Inc.38DChitogenX Inc.——Neighbors
Middlesex →Key facts
CEOLeo Ehrlich
SectorHealthcare
IndustryBiotechnology
HeadquartersWakefield, MA
ExchangeOTC: IPIX
Employees4
IPO date2007-05-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.